Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J Goodall

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Oncogene|July 12, 2011
FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cellsN McInnes, T J Sadlon, C Y Brown, et al.
Oncogene|August 27, 2013
Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancerS S Roy, V K Gonugunta, A Bandyopadhyay, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1993
The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor alpha and potentiates interleukin 8 secretion and neutrophil transmigrationE I Korpelainen, J R Gamble, W B Smith, et al.
The Journal of Biological Chemistry|March 18, 1994
Two contiguous residues in human interleukin-3, Asp21 and Glu22, selectively interact with the alpha- and beta-chains of its receptor and participate in functionS C Barry, C J Bagley, J Phillips, et al.
British Journal of Cancer|July 13, 2013
Circulating microRNAs predict biochemical recurrence in prostate cancer patientsL A Selth, S L Townley, A G Bert, et al.
Oncogene|November 27, 2013
Enhanced expression of transferrin receptor 1 contributes to oncogenic signalling by sphingosine kinase 1D H Pham, J A Powell, B L Gliddon, et al.
Blood|February 1, 1997
Roles of the N and C terminal domains of the interleukin-3 receptor alpha chain in receptor functionS C Barry, E Korpelainen, Q Sun, et al.
Blood|January 1, 1996
Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonistQ Sun, J M Woodcock, A Rapoport, et al.
Oncogene|July 17, 2012
Mutant p53 drives invasion in breast tumors through up-regulation of miR-155P M Neilsen, J E Noll, S Mattiske, et al.
Oncogene|September 17, 2013
MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathwaysX Li, S Roslan, C N Johnstone, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Oncogene|July 12, 2011
FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cellsN McInnes, T J Sadlon, C Y Brown, et al.
Oncogene|August 27, 2013
Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancerS S Roy, V K Gonugunta, A Bandyopadhyay, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1993
The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor alpha and potentiates interleukin 8 secretion and neutrophil transmigrationE I Korpelainen, J R Gamble, W B Smith, et al.
The Journal of Biological Chemistry|March 18, 1994
Two contiguous residues in human interleukin-3, Asp21 and Glu22, selectively interact with the alpha- and beta-chains of its receptor and participate in functionS C Barry, C J Bagley, J Phillips, et al.
British Journal of Cancer|July 13, 2013
Circulating microRNAs predict biochemical recurrence in prostate cancer patientsL A Selth, S L Townley, A G Bert, et al.
Oncogene|November 27, 2013
Enhanced expression of transferrin receptor 1 contributes to oncogenic signalling by sphingosine kinase 1D H Pham, J A Powell, B L Gliddon, et al.
Blood|February 1, 1997
Roles of the N and C terminal domains of the interleukin-3 receptor alpha chain in receptor functionS C Barry, E Korpelainen, Q Sun, et al.
Blood|January 1, 1996
Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonistQ Sun, J M Woodcock, A Rapoport, et al.
Oncogene|July 17, 2012
Mutant p53 drives invasion in breast tumors through up-regulation of miR-155P M Neilsen, J E Noll, S Mattiske, et al.
Oncogene|September 17, 2013
MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathwaysX Li, S Roslan, C N Johnstone, et al.
Pageof 5